Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099970 · ClinicalTrials.gov registry record · Phase 2
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
A Phase 2 study of Melanoma and Metastases, sponsored by PDL BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT00099970 is a Phase 2 study of Melanoma and Metastases that has completed, run by PDL BioPharma. The registered enrollment target is 40 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00099970, a Phase 2 study of Melanoma and Metastases, has completed, sponsored by PDL BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Conditions Studied
Interventions
- DRUG M200 (volociximab) in Combination with Dacarbazine (DTIC)
Study Locations (7)
California
- UCLA School of Medicine - Los Angeles
- Cancer Institute Medical Group, Inc. - Santa Monica
Alabama
- University of Alabama at Birmingham-Comprehensive Cancer Ctr. - Birmingham
Arizona
- Arizona Cancer Center - Tucson
Pennsylvania
- University of Pittsburgh - Pittsburgh
South Carolina
- Palmetto Hematology Oncology, P.C. - Spartanburg
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099970
The ClinicalTrials.gov registry entry for NCT00099970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The listed sponsor is PDL BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which M200 (volociximab) in Combination with Dacarbazine (DTIC) is the first listed.
NCT00099970 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00099970 about?
NCT00099970 is a clinical study titled "Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy". This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
What is the current status of trial NCT00099970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-12. Estimated completion is 2006-03.
What conditions does trial NCT00099970 study?
This clinical trial studies the following conditions: Melanoma, Metastases.
What interventions are being tested in trial NCT00099970?
The interventions under investigation include: M200 (volociximab) in Combination with Dacarbazine (DTIC) (DRUG).
Who is sponsoring clinical trial NCT00099970?
This trial is sponsored by PDL BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00099970 being conducted?
This trial has 7 study locations across Alabama, Arizona, California, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.